Eargo, Inc., a medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was founded in 2010 and is headquartered in San Jose, California.
IPO Year: 2020
Exchange: NASDAQ
Website: eargo.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/23/2021 | Outperform → Mkt Perform | William Blair | |
| 9/23/2021 | $11.00 | Overweight → Underweight | JP Morgan |
| 9/23/2021 | $10.00 | Overweight → Equal-Weight | Wells Fargo |
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
4 - Eargo, Inc. (0001719395) (Issuer)
William Blair downgraded Eargo from Outperform to Mkt Perform
JP Morgan downgraded Eargo from Overweight to Underweight and set a new price target of $11.00
Wells Fargo downgraded Eargo from Overweight to Equal-Weight and set a new price target of $10.00
Wells Fargo reiterated coverage of Eargo with a rating of Overweight and set a new price target of $52.00 from $68.00 previously
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13G/A - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13G - Eargo, Inc. (0001719395) (Subject)
SC 13D - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SC 13D/A - Eargo, Inc. (0001719395) (Subject)
SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t
SAN JOSE, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the appointment of Katie Bayne to its Board of Directors, effective June 9, 2021. Ms. Bayne will serve as a member of the Nominating and Corporate Governance Committee. The appointment of Ms. Bayne fills the seat vacated by Juliet Tammenoms Bakker, following her resignation from the Board on June 9, 2021. Christian Gormsen, President and CEO, said, “We are incredibly fortunate to welcome Katie to the Eargo team. She is exceptionally qualified and brings decades of experience building one of the mos
SAN JOSE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- This quarter, Eargo, Inc. launches two new over-the-counter (OTC) hearing wellness devices, Eargo SE (launching today) and LINK by Eargo (launching in the first quarter of 2024). The new devices expand the brand's portfolio of offerings with a new earbud form factor and a completely-in-canal option focused on Eargo signature essentials. For over a decade, Eargo has set the industry standard for pairing award-winning discreet and effortless hearing devices with ongoing expert support. These newest devices address additional consumer needs around functionality, design and experience. Key highlights of each product include: Eargo SE (MSRP$1
SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo") celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo's founding mission. The FDA has noted that the use of hearing aids has been associated with health benefits, improved social participation, and a better quality of life. Th
SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo's retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo's virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues
Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will
Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported
SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s
Recent Highlights: Net revenues of $12.9 million in the fourth quarter of 2022, compared to $10.1 million in the fourth quarter of 2021 and $7.9 million in the third quarter of 2022Gross systems shipped of 8,863, compared to 7,767 in the fourth quarter of 2021GAAP operating loss $23.9 million in the fourth quarter of 2022, compared to $45.2 million in the fourth quarter of 2021 and $26.0 million in the third quarter of 2022Cash and cash equivalents of $101.2 million as of December 31, 2022Prior debt balance fully extinguished following closing of the rights offering in November 2022 SAN JOSE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company
SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the fourth quarter 2022 after market close on March 23, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2951533. The live webinar of the call may also be accessed by visiting the Events and Presentati
SAN JOSE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) (the "Company" or "Eargo"), a medical device company on a mission to improve the quality of life of people with hearing loss, announced today that it received a letter from The Nasdaq Stock Market LLC ("Nasdaq") dated February 1, 2023 informing Eargo that the Company's minimum bid price deficiency has been cured. The letter from Nasdaq follows the Company's 1-for-20 reverse stock split approved by stockholders on October 12, 2022 and effected on January 17, 2023, after which the closing price of the Company's common stock was at least $1.00 per share for the 10 consecutive business days ended January 31, 2023. A
SAN JOSE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced that it has filed a Certificate of Amendment (the "Amendment") to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the previously announced 1-for-20 reverse stock split of the Company's common stock (the "Reverse Stock Split"). The Company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Stock Market LLC ("Nasdaq") at market open on January 18, 2023. The Company's common
15-12G - Eargo, Inc. (0001719395) (Filer)
S-8 POS - Eargo, Inc. (0001719395) (Filer)
S-8 POS - Eargo, Inc. (0001719395) (Filer)
S-8 POS - Eargo, Inc. (0001719395) (Filer)
RW - Eargo, Inc. (0001719395) (Filer)
SC 13E3/A - Eargo, Inc. (0001719395) (Subject)
25-NSE - Eargo, Inc. (0001719395) (Subject)
8-K - Eargo, Inc. (0001719395) (Filer)
8-K - Eargo, Inc. (0001719395) (Filer)
DEFA14A - Eargo, Inc. (0001719395) (Filer)
Recent Highlights: Net revenues of $8.1 million in the second quarter of 2023, up 12% year-over-yearGross systems shipped of 5,098, up 14% year-over-yearGAAP total operating loss $25.8 million in the second quarter of 2023, compared to $31.4 million in the second quarter of 2022In connection with the implementation of the announced cost reduction plan, the Company expects to extend net operating cash runway into the second half of 2024 SAN JOSE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported its financial results for the second quarter ended June 30, 2023. Will
Recent Highlights: Net revenues of $11.8 million in the first quarter of 2023, up 29% year-over-yearGross systems shipped of 8,705, up 51% year-over-yearGAAP total operating loss $22.8 million in the first quarter of 2023, compared to $30.4 million in the first quarter of 2022Commercially launched Eargo 7, a self-fitting hearing aid with the use of Sound Match via our mobile app, in February 2023Company expects modest sequential improvements to net operating cash burn in the remaining quarters of 2023 SAN JOSE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company"), a medical device company on a mission to improve hearing health, today reported
SAN JOSE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the first quarter 2023 after market close on May 11, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2789592. The live webinar of the call may also be accessed by visiting the Events and Presentations s
Recent Highlights: Net revenues of $12.9 million in the fourth quarter of 2022, compared to $10.1 million in the fourth quarter of 2021 and $7.9 million in the third quarter of 2022Gross systems shipped of 8,863, compared to 7,767 in the fourth quarter of 2021GAAP operating loss $23.9 million in the fourth quarter of 2022, compared to $45.2 million in the fourth quarter of 2021 and $26.0 million in the third quarter of 2022Cash and cash equivalents of $101.2 million as of December 31, 2022Prior debt balance fully extinguished following closing of the rights offering in November 2022 SAN JOSE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR) ("Eargo" or the "Company
SAN JOSE, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the fourth quarter 2022 after market close on March 23, 2023. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers, using conference ID: 2951533. The live webinar of the call may also be accessed by visiting the Events and Presentati
Third Quarter 2022 Highlights: Net revenues of $7.9 million, compared to ($22.9) million in the prior year periodGross systems shipped of 5,156, compared to 13,117 in the prior year periodReturn accrual rate of 32.3%, compared to 46.4% in the prior year periodGAAP gross margin of 24.0%; non-GAAP gross margin of 24.5%GAAP sales and marketing expense as a percent of net revenues of 142.7%; non-GAAP sales and marketing expense as a percent of net revenues of 134.5%Cash and cash equivalents of $88.1 million as of September 30, 2022Quarterly cash burn of approximately $19.0 millionAs of late October 2022, Eargo available for purchase in approximately 1,500 Victra Wireless stores nationwide throu
SAN JOSE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the third quarter 2022 after market close on November 3, 2022. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (888)-599-8686 for domestic callers or (323)-794-2588 for international callers, using conference ID: 8304019. The live webinar of the call may also be accessed by visiting the Events and Presentati
Conference Call to be held on Tuesday, October 4, 2022 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)VOTE now to ensure the Company can conduct its proposed rights offering and repay or convert the convertible notes held by Patient Square Capital SAN JOSE, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced it will hold an Investor Update conference call and webcast on Tuesday, October 4, 2022, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss details of its recently commenced proxy solicitation campaign for the 2022
Financing Update: Strengthened financial position with up to $125 million strategic investment from Patient Square Capital (the "Note Transaction"); closed first tranche investment of $100 million senior secured convertible notes on June 28, 2022Company intends to seek stockholder approval to increase number of authorized shares and issue full potential amount of note conversion shares at annual meeting of stockholders to be held on October 12, 2022Company is focused on completing rights offering of 375 million shares of common stock by November 25, 2022 Second Quarter 2022 Highlights: Reached civil settlement agreement with the U.S. Government to resolve the DOJ investigation with no adm
SAN JOSE, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. (NASDAQ:EAR), a medical device company on a mission to improve hearing health, today announced it will release financial results for the second quarter 2022 after market close on August 8, 2022. On the same day, Eargo will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (833) 630-0579 for domestic callers or (412) 317-1812 for international callers. Participants should ask to be joined into the Eargo call. The live webinar of the call may also be accessed by visit